Pfizer Inc. (PFE)

Scoop Up These 3 Bargain-Bin Dividend Stocks

Today, we'll be highlighting PFE, YORW, and UPS. The trio offers a market-crushing 5.8% yield, an A- blended S&P credit rating, and is trading 21% below fair value estimates. Pfizer appears to have the product portfolio and pipeline to return to modest growth. The York Water Company's capex spending and bolt-on acquisitions can fuel future growth.

Pfizer: Still A Bargain Despite Kennedy's Anti-Vaccine Attacks

Despite pressure from HHS Secretary RFK Jr. and pessimism from retail investors, Pfizer Inc.'s COVID-19 franchise sales were $808 million in Q2 2025, up 81.2% year-on-year. In addition, its oncology and tafamidis franchises once again helped Pfizer beat Wall Street analysts' expectations with wide margins. On the other hand, my fears that the launch of its next-generation drugs would be somewhat subdued were not realized.

Pfizer Inc. (NYSE: PFE) Price Prediction and Forecast 2025-2030 (September 2025)

Shares of Pfizer ( NYSE: PFE ) gained 4.50% over the past month after losing 6.50% the month prior.

Want $5,000 a Year In Passive Income? Buy These 3 Dividend Stocks and Hold for 5 Years

Investors looking to create meaningful passive income streams for retirement have a number of considerations to keep in mind.

Pfizer defends COVID-19 vaccine effectiveness after Trump remarks

Pfizer on Wednesday defended the effectiveness of its COVID-19 vaccine, saying it has saved more than 14 million lives worldwide, after U.S. President Donald Trump urged pharmaceutical companies to justify the success of their pandemic drugs.

Pfizer's Golden Cross Signals Strength: How to Play the Stock

Pfizer trades above key SMAs with a golden cross, while new drugs and cost cuts drive growth despite looming headwinds.

7 Big Yields From The Beat-Up Healthcare Sector

Healthcare stocks haven't moved since the April lows. As contrarian investors, this neglect piques our interest.

Trump tells drugmakers to 'justify the success' of Covid meds after FDA limits vaccine approval

President Donald Trump called on pharmaceutical companies to "justify the success" of their Covid drugs days after the FDA set new limits on who can receive vaccines for the virus. Trump last week fired Centers for Disease Control and Prevention's Director Susan Monarez after she refused to resign.

FDA Approves Updated COVID-19 Vaccines but With Restrictions

FDA clears updated COVID-19 vaccines from Pfizer, Moderna and Novavax but limits access to older adults and high-risk groups.

Pfizer: At $25 Is PFE Stock Deep Value Or A Falling Knife?

After losing nearly half its value from its 2021 highs, Pfizer stock (NYSE: PFE) now trades at about $25, presenting a potentially attractive value setup. As the company continues to adapt to a post-pandemic environment with normalized COVID-19 vaccine demand, its solid fundamentals and a compelling 6.9% dividend yield point to an interesting opportunity for long-term, risk-adjusted returns.

Can Pfizer's Cost Cuts and New Drugs Offset Upcoming Headwinds?

Pfizer braces for patent losses, IRA pressure and COVID uncertainty, but cost cuts and key drugs may still support profit growth.

Pfizer: A 6% Dividend Yield That Pays You To Stay Defensive

Pfizer is deeply undervalued, trading at a multi-year low with a 6.65% dividend yield, making it a compelling long-term opportunity. Recent double-digit earnings growth, strong margins, and cost optimization efforts support my $33 price target and Strong Buy rating. Valuation metrics show Pfizer is significantly cheaper than peers, with limited downside risk and a stable, high-quality business model.

Pfizer and BioNTech's COMIRNATY® Receives U.S. FDA Approval for Adults 65 and Older and Individuals Ages 5 through 64 at Increased Risk for Severe COVID-19

NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for the companies' LP.8.1-adapted monovalent COVID-19 vaccine (COMIRNATY® LP.8.1; COVID-19 Vaccine, mRNA) for use in adults ages 65 years and older, as well as in individuals ages 5 through 64 years with at least one underlying condition that puts the.

LLY vs. PFE: Which Pharma Giant Is the Better Pick for Investors?

Pfizer's cost cuts, new products and cheaper valuation give it an edge over Eli Lilly despite LLY's strong GLP-1 momentum.

Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know

Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Pfizer: Shares Are Cheap, But They Could Get Even Cheaper Next Year

I remain bearish on Pfizer due to pricing pressures from IRA/340B and a looming 2026 patent cliff, despite Q2 2025 earnings beat. Cost-cutting measures have lifted EPS above expectations and could deliver $7.7B in savings by 2027, but in my view, these are not a substitute for topline growth. IRA Part D redesign and 340B discounts are already pressuring sales (e.g., Nurtec flat yoy despite 47% U.S. market share). I expect more products like Vyndaqel to be pressured.

Pfizer Oncology Drugs Drive Sales in Q2: Will the Trend Continue?

Pfizer's oncology portfolio, boosted by Seagen and strong drug sales, fuels Q2 growth and positions the company for future cancer treatment gains.

Pfizer experimental sickle cell drug fails phase 3 trial

CNBC's Angelica Peebles joins 'Squawk on the Street' with the latest news on drugmaker Pfizer.

3 Cheap Dividend Stocks With Excellent Yields

PFE New & Acquired Drugs Back 1H Top-Line Growth: Will the Trend Last?

Pfizer's new and acquired drugs record sales of $4.7B in H1 as COVID-products related volatility eases.

FDA may revoke Pfizer COVID-19 vaccine authorization for kids under certain age

The Food and Drug Administration could pull Pfizer's coronavirus vaccine emergency authorization for children under age 5.

FDA may pull authorization of Pfizer's Covid vaccine for children under 5

The Food and Drug Administration is weighing revoking its authorization of Pfizer's Covid-19 vaccine for healthy children under the age of 5, the drugmaker confirmed to CNBC. The move could leave many kids with no available shots against the virus.

Should Pfizer Stock Be in Your Portfolio After Solid Q2 Results?

Pfizer posts strong Q2 earnings and raises EPS outlook, with oncology growth and new drugs offsetting looming headwinds.

Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know

Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

4 High-Yield Blue Chips Near 52-Week Lows: All Are Strong Buys Now

Blue-chip stocks are shares of large, well-established, financially stable companies with a history of consistent and reliable performance.

Pfizer Q2 Earnings Review: Upside At Last As CEO Prepares For Trump Policy Battle

Pfizer delivered a strong Q2 2025, beating revenue and EPS estimates, raising EPS guidance, and maintaining its attractive dividend yield above 7%. Product portfolio strength is evident, with growth in Primary Care, Specialty Care, and Oncology, but looming patent expiries and regulatory risks persist. Management's financial discipline is improving, with cost savings, debt management, and a focus on extracting value from recent M&A deals.

Pfizer Q2 Earnings Beat Estimates, Oncology Drives Top-Line Growth

PFE posts strong Q2 results with earnings up 30% and revenues up 10% year over year, fueled by rising oncology sales and cost cuts.

Trade Deficit Narrowed More Than Expected

Pre-market futures are in the green across major indexes this morning, but experiencing a bit of choppiness. The Dow and S&P 500 are both up mere single-digits at this hour, off the early-morning highs, while the tech-heavy Nasdaq stays up +70 points presently.

Pfizer Stock Pops on Q2 Beat-and-Raise

The shares of Pfizer Inc (NYSE:PFE) were last seen up 4.9% to trade at $24.4, after the pharmaceutical giant's second-quarter results beat expectations.

Here's What Key Metrics Tell Us About Pfizer (PFE) Q2 Earnings

While the top- and bottom-line numbers for Pfizer (PFE) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.